INC. (NASDAQ:INCR) Files An 8-K Entry into a Material Definitive Agreement

INC. (NASDAQ:INCR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On February 17, 2021, SunHydrogen, Inc. (the “Company”) entered into a cooperation agreement with Gebr. SCHMID GmbH (“SCHMID”), effective March 1, 2021, to which SCHMID will provide a concept for customized manufacturing equipment for the Company’s technology, particularly its Gen 2 NanoParticle hydrogen generator. The Company agreed to pay SCHMID €800,000 in consideration for its services. The agreement has an initial term of six months and includes customary confidentiality and indemnification provisions.

The foregoing description of the cooperation agreement is qualified by reference to the full text of the agreement which is filed as an exhibit to this report.

Item 9.01 Financial Statements and Exhibits.

10.1 Cooperation Agreement


SUNHYDROGEN, INC. Exhibit
EX-10.1 2 ea136141ex10-1_sunhydrogen.htm COOPERATION AGREEMENT Exhibit 10.1   Cooperation Agreement   between   SunHydrogen,…
To view the full exhibit click here

Story continues below

About INC. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

An ad to help with our costs